T2D= Type 2 Diabetes. CKD=  Chronic Kidney disease. The information presented is based on the FLOW study and is consistent with the approved label. Semaglutide 1 mg (Ozempic) is indicated for the treatment of adults with insufficiently controlled T2D as an adjunct to diet and exercise. Kidney composite outcome included: onset of kidney failure (dialysis, transplantation, or an eGFR of <15 ml per minute per 1.73m2), at least a 50% reduction in the eGFR from baseline, or death from kidney-related or cardiovascular causes.
 
1- Perkovic et al. N Engl J Med 2024; 391:109-121
2- Standards of Care in Diabetes - 2025: Diabetes Care, January 2025, Vol.48

For complete information please refer to the updated physician leaflet in the MOH website. For information on the approved product's indications, most common adverse events, and significant warnings, enter the following link:  Ozempic_aPI
Need additional information? contact the Marketing Authorization Holder at:  www.novonordisk.co.il
 
IL25OZM00133